1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (011) (44) 0115-9627768
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Prognostic markers in triple-negative breast cancer
Article first published online: 4 DEC 2006
DOI: 10.1002/cncr.22381
Copyright © 2006 American Cancer Society
Additional Information
How to Cite
Rakha, E. A., El-Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F. and Ellis, I. O. (2007), Prognostic markers in triple-negative breast cancer. Cancer, 109: 25–32. doi: 10.1002/cncr.22381
- †
Fax: (011) (44) 0115-9627768
Publication History
- Issue published online: 11 DEC 2006
- Article first published online: 4 DEC 2006
- Manuscript Accepted: 10 OCT 2006
- Manuscript Revised: 6 OCT 2006
- Manuscript Received: 7 SEP 2006
REFERENCES
- 1, , , et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747–752.
- 2, , , et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006; 5: 24.
- 3, , , et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005; 116: 340–350.
- 4, , , et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418–8423.
- 5, , , et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869–10874.
- 6, , , et al. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006; 98: 1011–1014.
- 7, , , , , . Estrogen receptor protein of breast cancer in patients with positive nodes. High recurrence rates in the postmenopausal estrogen receptor-negative group. Arch Surg. 1987; 122: 1303–1306.
- 8, , , . Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer. 1984; 54: 2237–2242.
- 9, , , et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 1996; 73: 1545–1551.
- 10, , . Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins. Histopathology. 1999; 35: 241–248.Direct Link:
- 11, . Secretory carcinoma of the breast. Arch Pathol Lab Med. 1991; 115: 141–144.
- 12, , , , . Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology. 1997; 30: 523–532.
- 13, . Dysregulation of cellular signaling by HER2/ neu in breast cancer. Semin Oncol. 2003; 30(5 suppl 16 ): 38–48.
- 14, . An overview of HER2. Semin Oncol. 2001; 28(6 suppl 18 ): 3–11.
- 15, , , et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer. 1994; 74: 2956–2963.
- 16. c-erb-B2 expression and response to treatment in metastatic breast cancer. Med Oncol. 2000; 17: 22–28.
- 17, , , et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004; 203: 661–671.
- 18, , , et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006; 208: 495–506.
- 19, , , . The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22: 207–219.
- 20, , , , , . The prognosis of small primary breast cancers. Eur J Cancer. 1999; 35: 908–912.
- 21, , , et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: 844–847.
- 22, , . Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000; 80: 1943–1949.
- 23, , , et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91: 1532–1542.
- 24, , . Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002; 52: 186–194.
- 25, , . Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001; 6: 375–392.
- 26, , . The Breast. Vol 3. 7th ed. Philadelphia: Elsevier; 2004.
- 27, , , et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006; 17: 818–826.
- 28, , , . Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001; 195: 41–52.
- 29, , , et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005; 18: 26–35.
- 30, . Morphologic spectrum of estrogen receptor-negative breast carcinoma. Arch Pathol Lab Med. 2002; 126: 325–330.
- 31, , , et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992; 10: 1049–1056.
- 32
- 33, , . Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006; 19: 617–621.
- 34, , , et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492–2502.
- 35, , , , , . Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep. 2005; 14: 337–343.
- 36, . Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403–410.
- 37
- 38, , , , , . The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 years. Cancer. 2000; 88: 804–813.
- 39, , . Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181–187.
- 40, , , et al. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res. 2004; 24: 2061–2068.
- 41, , , , , . The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol. 2001; 14: 650–654.
- 42, , , et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer. 2001; 85: 1958–1963.
- 43, , , . Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998; 433: 119–129.
- 44, , , , , . Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005; 69: 478–485.
- 45, , , et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002; 161: 1991–1996.
- 46, , , et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996; 32A: 1560–1565.
- 47, , , , . Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003; 120: 725–731.
- 48, , , . The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori. 2005; 91: 46–52.